CClinicalTrials.gg
CompletedNCT03450499Updated Aug 20, 2019

Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section

A Phase 4 interventional study of Ketamine and Placebo in Non Elective Cesarean Section and Ketamine Analgesia, sponsored by B.P. Koirala Institute of Health Sciences. Completed at 1 site in Nepal. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2019-08-20.

Sponsored by B.P. Koirala Institute of Health Sciences · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This randomized double blind study will be conducted in pregnant woman planned for non elective cesarean section under spinal anesthesia. Ketamine group will receive intravenous 0.25 mg/kg and placebo group will receive same amount of normal saline after spinal anesthesia prior to skin incision. Postoperative outcomes measures are total opioid consumption and pain scores for 24 hrs.

02

Conditions studied

  • Non Elective Cesarean Section and Ketamine Analgesia

Browse trials for

03

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

    • All women at term(>or =37 weeks of gestation)

      • Healthy
      • American Society of Anesthesiologists(ASA) class1 and 2
      • Women undergoing non-elective caesarean section whose anesthetic plan is for spinal anesthesia with bupivacaine and fentanyl

Exclusion criteria

Exclusion Criteria:

    • Women with American society of anesthesiologist physical status>2

      • Body mass index >or =40 kg per square meter
      • Height \<150 cm
      • Any contraindication to the spinal anesthesia
      • History of substance abuse
      • History of hallucinations
      • Chronic opioid therapy
      • Chronic pain or on any pain medication currently
      • Patient with maternal complications,like cardiovascular disease pre-eclampsia,diabetes,multiple gestation,known fetal abnormality
      • Cases with severely compromised fetus where immediate administration of general anesthesia is required.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    analgesic effects of ketamine

    the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.

    Drug: Ketamine

  • Placebo comparator
    placebo

    they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.

    Drug: Placebo

Interventions

  • DrugKetamine

    the analgesic affects of ketamine will be compared between the experimental and placebo group.

    Also known as: ketamine hydrochloride

  • DrugPlacebo

    the analgesic requirement will be calculated in placebo group.

05

What researchers measure

Primary outcomes

  1. Total opioid requirement postoperatively

    Total opioid required up to 24 postoperatively in ketamine and placebo group.

    Time frame: 24 hrs

Secondary outcomes

  1. Postoperative numerator rating scores(NRS)up to 24 hrs . postoperative )

    • Postoperative NRS Scores (on arrival to Post operative care unit), 2, 4, 6, 8, 12 and 24 h ).The NRS ranges from 0- 10 and 0 refers to no pain and 10 means extreme possible pain perceived.

    Time frame: 24 hrs

  2. Time to first perception of pain

    Time to first perception of pain

    Time frame: 24 hrs

  3. Incidence of side effects

    Incidence of post operative nausea and vomiting, shivering, sedation scores, side effects related to ketamine during the first 24h

    Time frame: 24 hrs

06

Study locations

1 site
  • BP Koirala Institute of Health Sciences (BPKIHS)
    Dharān Bāzār, Koshi 56700, Nepal
07

References and documents

Publications

  • Adhikari P, Subedi A, Sah BP, Pokharel K. Analgesic effects of intravenous ketamine after spinal anaesthesia for non-elective caesarean delivery: a randomised controlled trial. BMJ Open. 2021 Jun 30;11(6):e044168. doi: 10.1136/bmjopen-2020-044168. PubMed 34193480 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03450499
Lead sponsor
B.P. Koirala Institute of Health Sciences
Responsible party
prahlad adhikari (doctor, B.P. Koirala Institute of Health Sciences) — Principal investigator
First posted
Mar 1, 2018
Start date
Apr 1, 2018
Primary completion
Mar 7, 2019
Completion
Mar 7, 2019
Last update
Aug 20, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion